A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer

Clinical trial NCT06957886 · RECRUITING

Trial details

NCT number: NCT06957886
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

HER2-low Breast Cancer

Start date: 2025-05-15
Primary completion: 2027-05-01
Enrollment: 566

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.